Risedronate’s efficacy: from randomized clinical trials to real clinical practice

Iolascon, Giovanni and Sirico, Felice and Ferrante, Alberto and Gimigliano, Raffaele and Gimigliano, Francesca (2010) Risedronate’s efficacy: from randomized clinical trials to real clinical practice. Clinical cases in mineral and bone metabolism, 7 (1). pp. 19-22. ISSN 1971-3266

Preview

PDF portiere.php.pdf - Published Version Download (497kB)

Abstract

Osteoporosis represents the most common human bone disorder with a large medical and economical burden on the Health Care System. Bisphosphonates are the major drugs used for the treatment of osteoporosis. Differences in their chemical structures and pharmacokinetic actions can explain the different clinical efficacy among these molecules. Risedronate is a potent inhibitor of farnesyl pyrophosphate synthase, but does not bind strongly to mineral; this lower mineral binding may enable risedronate to have a wider distribution in bone. Its antifracture efficacy has been established in several randomized phase III controlled studies that showed its value in the reduction of vertebral, non vertebral and hip fractures. Randomized controlled trials and observational studies demonstrated risedronate efficacy and safety in different subsets of patients, therefore risedronate is configured, among oral therapies currently available for osteoporosis, as a drug of first choice

Item Type:	Article
Uncontrolled Keywords:	Risedronate, osteoporosis, drug therapy
Subjects:	600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 611 Anatomia; Citologia; Istologia umana > 611.7 Sistema muscoloscheletrico, tegumento
Depositing User:	Danilo Dezzi
Date Deposited:	14 Jan 2014 10:46
Last Modified:	14 Jan 2014 10:46
URI:	http://eprints.bice.rm.cnr.it/id/eprint/5585

Actions (login required)

View Item